The Equine Surgery Service in Iowa State University’s College of Veterinary Medicine is seeking horses with sarcoid or squamous cell carcinomas for a clinical study. Horses with tumors of 5 cm diameter or less will be enrolled and treated with Immunocidin® Equine.
The Iowa State study is focused on standardizing treatment protocols and assessing the product’s efficacy and safety in the treatment of both sarcoids and squamous cell carcinoma.
Initial work-up will include history, physical examination, a small (4-6 mm) tumor biopsy will be taken, and tumor measurement and photography will be performed. Biopsies will be evaluated to establish a histopathologic diagnosis. Local injection of the tumor will be completed on an outpatient basis. Horses will receive examination and treatments every 14 days. If no visible tumor is present at recheck, then an additional 14-day recheck will be recommended. If the tumor is still visible, an additional treatment will be performed at that time. If no response is seen after 4 injections, Immunocidin treatment will be discontinued. Tumors will be photographed and measured at each visit prior to re-injection.
Clients will be responsible for exam fees and other medications (such as anti-inflammatories) needed beyond the immunotherapy. The study protocol will cover the additional costs.
Dr. Stephanie Caston, DVM, DACVS-LA, associate professor of equine surgery in the College of Veterinary Medicine, is the principal investigator. Immunocidin® Equine has regulatory approval in the U.S. and Canada for treatment of equine sarcoid tumors.
More information is available at https://www.bloodhorse.com/horse-racing/articles/225047/iowa-state-to-study-equine-anticancer-immunotherapeutic.
Contact Caston to be included in the survery.